Integra LifeSciences Holdings (IART) is a publicly traded Healthcare sector company. As of May 21, 2026, IART trades at $15.40 with a market cap of $1.10B and a P/E ratio of -2.33. IART moved +7.06% today. Year to date, IART is +22.53%; over the trailing twelve months it is +15.54%. Its 52-week range spans $8.70 to $27.13. Analyst consensus is neutral with an average price target of $15.60. Rallies surfaces IART's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Integra sees 2.4% Q1 revenue growth to $391.9M and names new CEO: Integra reported Q1 2026 revenues of $391.9 million, up 2.4% reported and 1.3% organic, with adjusted EPS rising to $0.54 from $0.41. The company reaffirmed full-year revenue guidance at $1.662–1.702 billion and updated adjusted EPS guidance to $2.40–2.50, while appointing Stuart Essig as president and CEO and Michael McBreen as chief commercial officer.
| Metric | Value |
|---|---|
| Price | $15.40 |
| Market Cap | $1.10B |
| P/E Ratio | -2.33 |
| EPS | $-6.46 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.13 |
| 52-Week Low | $8.70 |
| Volume | 112 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.64B |
| Net Income | $-495.80M |
| Gross Margin | 51.94% |
8 analysts cover IART: 0 strong buy, 1 buy, 4 hold, 3 sell, 0 strong sell. Consensus rating is neutral. Average price target: $15.60.